• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    FibroGen Appoints David DeLucia as Chief Financial Officer

    12/16/24 8:05:00 AM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FGEN alert in real time by email

    SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024.

    Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury.

    "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabilities required to lead our finance organization and be a key member of our leadership team," said Thane Wettig, Chief Executive Officer of FibroGen. "His deep understanding of all aspects of our business, along with his proven track record and strategic insights will be invaluable in his new role as CFO as we advance FG-3246, a first-in-class ADC targeting CD46, and its companion diagnostic FG-3180, while further building on the strong performance of roxadustat."

    "I am thrilled to take on the role of CFO at FibroGen and to help lead the company at this important time," said DeLucia. "With our recent transformation into a lean and focused organization, I believe we are well positioned for an exciting future and look forward to continued execution on our strategic vision to bring novel therapies forward for cancer and cancer-related conditions."

    Mr. DeLucia has nearly 15 years of financial leadership and experience within the life sciences industry. Prior to joining FibroGen in 2022, he held positions of increasing responsibility at TherapeuticsMD, overseeing Financial Planning and Analysis, Corporate Development, and Investor Relations. Earlier in his career, he was a buy-side investor at JP Morgan Asset Management, covering small and mid-cap healthcare companies.

    Mr. DeLucia holds the Chartered Financial Analyst® designation and a dual degree of Bachelor of Business Administration in Finance & Accounting and Bachelor of Science in Economics from the University of Michigan - Stephen M. Ross School of Business.

    About FibroGen

    FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET imaging agent, FG-3180. In addition, FibroGen's research and development portfolio includes two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding FibroGen's strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the potential clinical or commercial success of FibroGen products and product candidates, and statements about FibroGen's plans and objectives. These forward-looking statements are typically identified by use of terms such as "may," "will", "should," "on track," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. FibroGen's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

    Contact:

    David DeLucia, CFA

    Vice President of Corporate FP&A / Investor Relations

    [email protected]



    Primary Logo

    Get the next $FGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FGEN

    DatePrice TargetRatingAnalyst
    8/8/2023$4.00 → $2.00Neutral → Underperform
    BofA Securities
    6/26/2023Buy → Hold
    Stifel
    6/26/2023Buy → Neutral
    BofA Securities
    6/26/2023Outperform → Mkt Perform
    Raymond James
    6/26/2023Outperform → Mkt Perform
    William Blair
    6/2/2023$23.00 → $32.00Hold → Buy
    Stifel
    1/31/2023Mkt Perform → Outperform
    William Blair
    1/26/2023$35.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $FGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by FibroGen Inc

      SC 13G/A - FIBROGEN INC (0000921299) (Subject)

      11/14/24 4:52:23 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by FibroGen Inc

      SC 13G/A - FIBROGEN INC (0000921299) (Subject)

      11/12/24 4:01:23 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by FibroGen Inc

      SC 13G/A - FIBROGEN INC (0000921299) (Subject)

      11/12/24 2:33:26 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      3/25/25 9:00:05 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schoeneck James A bought $105,040 worth of shares (300,000 units at $0.35) (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      3/24/25 9:00:05 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Adib Deyaa bought $25,884 worth of shares (22,123 units at $1.17), increasing direct ownership by 37% to 82,123 units (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      6/13/24 4:30:17 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • FibroGen Appoints David DeLucia as Chief Financial Officer

      SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili

      12/16/24 8:05:00 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

      SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him

      3/11/24 7:00:00 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Announces Leadership Transition

      Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the appointment of Thane Wettig as the Company's interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen's Chief Commercial Officer and a key member of the senior leadership team since June 2020. Mr. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period. "Than

      7/25/23 7:00:00 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      3/25/25 9:00:05 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schoeneck James A bought $105,040 worth of shares (300,000 units at $0.35) (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      3/24/25 9:00:05 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Wettig Thane covered exercise/tax liability with 22,405 shares and was granted 781 shares, decreasing direct ownership by 5% to 398,329 units (SEC Form 4)

      4 - FIBROGEN INC (0000921299) (Issuer)

      3/7/25 7:03:52 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    SEC Filings

    See more
    • SEC Form DEFA14A filed by FibroGen Inc

      DEFA14A - FIBROGEN INC (0000921299) (Filer)

      4/25/25 5:05:02 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by FibroGen Inc

      DEF 14A - FIBROGEN INC (0000921299) (Filer)

      4/25/25 5:00:18 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by FibroGen Inc

      PRE 14A - FIBROGEN INC (0000921299) (Filer)

      4/17/25 5:00:53 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FibroGen to Report First Quarter 2025 Financial Results

      SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by pho

      5/5/25 4:05:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

      SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen's management team will be available for one-on-one meetings on Wednesday, April 9th. Interested investors should contact their representative at Needham. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) pat

      4/2/25 4:05:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

      FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025 SAN FRANCISCO, March 28, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the peer-reviewed publication titled "A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration Resistant Prostate Cancer" in the Journal of Clinical Oncology. The manuscript includes the complete results from the Fortis Therapeutics-sponsored Phase 1 study of FO

      3/28/25 7:00:00 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    Financials

    Live finance-specific insights

    See more
    • FibroGen to Report First Quarter 2025 Financial Results

      SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by pho

      5/5/25 4:05:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

      Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025 FibroGen to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, March 17, 2025

      3/17/25 4:05:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

      SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To acc

      3/3/25 4:45:00 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • FibroGen downgraded by BofA Securities with a new price target

      BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously

      8/8/23 6:27:35 AM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen downgraded by Stifel

      Stifel downgraded FibroGen from Buy to Hold

      6/26/23 1:22:02 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroGen downgraded by BofA Securities

      BofA Securities downgraded FibroGen from Buy to Neutral

      6/26/23 1:16:35 PM ET
      $FGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care